Literature DB >> 25963949

Epigenetic Regulation of Dopamine Transporter mRNA Expression in Human Neuroblastoma Cells.

Ashley L Green1, Muhammad M Hossain, Siew C Tee, Helmut Zarbl, Grace L Guo, Jason R Richardson.   

Abstract

The dopamine transporter (DAT) is a key regulator of dopaminergic neurotransmission. As such, proper regulation of DAT expression is important to maintain homeostasis, and disruption of DAT expression can lead to neurobehavioral dysfunction. Based on genomic features within the promoter of the DAT gene, there is potential for DAT expression to be regulated through epigenetic mechanisms, including DNA methylation and histone acetylation. However, the relative contribution of these mechanisms to DAT expression has not been empirically determined. Using pharmacologic and genetic approaches, we demonstrate that inhibition of DNA methyltransferase (DNMT) activity increased DAT mRNA approximately 1.5-2 fold. This effect was confirmed by siRNA knockdown of DNMT1. Likewise, the histone deacetylase (HDAC) inhibitors valproate and butyrate also increased DAT mRNA expression, but the response was much more robust with expression increasing over tenfold. Genetic knockdown of HDAC1 by siRNA also increased DAT expression, but not to the extent seen with pharmacological inhibition, suggesting additional isoforms of HDAC or other targets may contribute to the observed effect. Together, these data identify the relative contribution of DNMTs and HDACs in regulating expression. These finding may aid in understanding the mechanistic basis for changes in DAT expression in normal and pathophysiological states.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25963949      PMCID: PMC4745645          DOI: 10.1007/s11064-015-1601-6

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  36 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  An evaluation of new criteria for CpG islands in the human genome as gene markers.

Authors:  Yong Wang; Frederick C C Leung
Journal:  Bioinformatics       Date:  2004-02-05       Impact factor: 6.937

3.  Transcriptional initiation is controlled by upstream GC-box interactions in a TATAA-less promoter.

Authors:  M C Blake; R C Jambou; A G Swick; J W Kahn; J C Azizkhan
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

4.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

5.  Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated.

Authors:  M Höller; G Westin; J Jiricny; W Schaffner
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

6.  Studies in postmortem dopamine uptake. II. Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia.

Authors:  N Haberland; L Hetey
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

7.  Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1.

Authors:  Piia Aarnisalo; Chae-Hee Kim; Jae Woon Lee; Thomas Perlmann
Journal:  J Biol Chem       Date:  2002-07-18       Impact factor: 5.157

8.  DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.

Authors:  Marie-France Robert; Steves Morin; Normand Beaulieu; France Gauthier; Ian C Chute; Annie Barsalou; A Robert MacLeod
Journal:  Nat Genet       Date:  2002-12-23       Impact factor: 38.330

Review 9.  Monoamine transporters: from genes to behavior.

Authors:  Raul R Gainetdinov; Marc G Caron
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-09-17       Impact factor: 13.820

10.  Direct regulation of Pitx3 expression by Nurr1 in culture and in developing mouse midbrain.

Authors:  Floriana Volpicelli; Roberto De Gregorio; Salvatore Pulcrano; Carla Perrone-Capano; Umberto di Porzio; Gian Carlo Bellenchi
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  4 in total

1.  Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1.

Authors:  Ashley L Green; Le Zhan; Aseel Eid; Helmut Zarbl; Grace L Guo; Jason R Richardson
Journal:  Neuropharmacology       Date:  2017-07-22       Impact factor: 5.250

Review 2.  Valproate-Associated Parkinsonism: A Critical Review of the Literature.

Authors:  Florian Brugger; Kailash P Bhatia; Frank M C Besag
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

3.  Epigenetic Regulation of the Ontogenic Expression of the Dopamine Transporter.

Authors:  Ashley L Green; Aseel Eid; Le Zhan; Helmut Zarbl; Grace L Guo; Jason R Richardson
Journal:  Front Genet       Date:  2019-11-04       Impact factor: 4.599

4.  5-Azacytidine upregulates melatonin MT1 receptor expression in rat C6 glioma cells: oncostatic implications.

Authors:  Emily E Hartung; Sumeya Z Mukhtar; Syeda M Shah; Lennard P Niles
Journal:  Mol Biol Rep       Date:  2020-05-14       Impact factor: 2.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.